Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Phase Distribution

Ph not_applicable

17%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(3)

Other(1)

Detailed Status

Withdrawn3

Completed2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (80.0%)

N/A1 (20.0%)

Trials by Status

unknown117%

completed233%

withdrawn350%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

Clinical Trials (6)

Showing 6 of 6 trials

NCT02793856Phase 1

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

Completed

NCT03081715Not Applicable

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Completed

NCT02867345

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Withdrawn

NCT02863913Phase 1

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Withdrawn

NCT02867332Phase 1

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Withdrawn

NCT03525652Phase 1

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

Unknown

All 6 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 6